Myrobalan Therapeutics is a technology company.
Myrobalan Therapeutics has raised $24.0M across 1 funding round.
Myrobalan Therapeutics has raised $24.0M in total across 1 funding round.
Myrobalan Therapeutics is a biotechnology company developing oral small molecule therapies targeting demyelination and neuroinflammation to treat CNS conditions like ALS, multiple sclerosis, Alzheimer's, and Parkinson's.[1][2][3] Its lead program, MRO-001 (CSF1R inhibitor), addresses neuroinflammation in ALS and aims to be IND-ready by mid-2025, funded by the ALS Association, while MRO-002 (GPR17 antagonist) promotes myelin repair with an IND filing planned for 2026, supported by the National Multiple Sclerosis Society.[2][5] Headquartered in Medford, Massachusetts, the company has raised $43M+ in funding ($10M seed, $24M Series A first closing, $9M additional), employs under 25 people, and generates ~$5.1M in revenue, focusing on brain-penetrant drugs for unmet needs in neurodegenerative diseases.[1][4]
Myrobalan Therapeutics emerged from groundbreaking research by scientific co-founders Professor Zhigang He (Harvard) and Professor Guoping Feng (MIT), who in 2020 published in *Neuron* on CSF1R and GPR17's roles in remyelination and anti-neuroinflammation, prompting a shift to these novel mechanisms.[3][4] The company was incorporated shortly after, with Dr. Jing Wang, a co-founder, appointed CEO.[4] Key milestones include raising $10M seed funding, opening labs in Cambridge/Watertown, MA, and Nanjing, China (via subsidiary), graduating to Medford operations, joining J-Labs Shanghai, nominating a preclinical CSF1R candidate, securing an ALS Association grant, a $24M Series A (first closing), and $9M more financing, plus adding advisors and board member Grant Bogle.[4]
Myrobalan rides the neurorestorative wave in biotech, targeting root causes like neuroinflammation and demyelination amid rising CNS disease prevalence (e.g., ALS, MS, Alzheimer's), where current therapies fail to reverse pathology.[1][3][5] Timing aligns with advances in microglia modulation and remyelination research, plus precision neurology via biomarkers, fueled by market forces like aging populations and $100B+ neurodegenerative drug market.[3] It influences the ecosystem by translating academic breakthroughs (Harvard/MIT) into clinical candidates, bridging U.S.-China biotech, and securing nonprofit grants that de-risk early CNS programs.[2][4]
Myrobalan is poised for IND filings in 2025-2026, potentially advancing MRO-001 into ALS trials and MRO-002 for MS/neurodegenerative indications, with Series A extension funding supporting preclinical-to-clinical transition.[2][4] Trends like AI-driven drug discovery, microglial therapies, and remyelination platforms will shape its path, amplifying influence if Phase 1 data validate brain penetration and efficacy. As a nimble biotech with elite pedigrees, it could redefine oral CNS treatments, evolving from seed-stage innovator to pipeline leader in restorative neurology—tying back to its mission of harnessing novel mechanisms for brain repair.[3][5]
Myrobalan Therapeutics has raised $24.0M in total across 1 funding round.
Myrobalan Therapeutics's investors include 3E Bioventures Capital.
Myrobalan Therapeutics has raised $24.0M across 1 funding round. Most recently, it raised $24.0M Series A in January 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2024 | $24.0M Series A | 3E Bioventures Capital |